ACTRN12622000309785
Withdrawn
未知
Therapies to prevent progression of COVID-19, including Quercetin, Zinc, high dose Vitamin D with or without Intravenous Vitamin C, a multi-centre, international, randomized trial: The International ALLIANCE Study - Stage 2
AProf Dr Karin Ried0 sites200 target enrollmentFebruary 18, 2022
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- COVID-19
- Sponsor
- AProf Dr Karin Ried
- Enrollment
- 200
- Status
- Withdrawn
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diagnosis of active COVID\-19
- •Provision of informed consent in writing, can be electronic
Exclusion Criteria
- •1\) Known G6PD deficiency
- •2\) Contra\-indication to quercetin or Vitamin C: allergy to study interventions, epilepsy, serious hearing or visual problems, history of severe depression, calcium oxalate stones, advanced liver disease, pregnancy or lactating
- •3\) Already receiving quercetin, or more than 3 grams Vitamin C daily or an experimental antiviral
- •4\) History of fever (e.g. night sweats, chills) and/or acute respiratory infection (e.g. cough, shortness of breath, sore throat) of more than 7 days’ duration. Note, if study numbers not quickly reached, the investigators may decide to include those with symptoms of longer than 7 days
- •5\) Calculated creatinine clearance of less than 30 mL/minute
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
International ALLIANCE Study of Therapies to prevent progression of COVID-19, a randomized trialCOVID-19Infection - Other infectious diseasesRespiratory - Other respiratory disorders / diseasesACTRN12620000557932AProf Dr Karin Ried446
Recruiting
Phase 1
Therapies to prevent progression of COVID-19 in outpatients: The 'Primary Care Australian COVID-19 Therapeutics' (PACT) TrialACTRN12622000386730AProf Dr Karin Ried300
Not yet recruiting
Phase 3
Prevention and treatment for covid-19 associated severe pneumonia in The Gambia: a randomized clinical trial (PaTS-COVID) COVID-19PACTR202101544570971Medical Research Council Unit The Gambia at LSHTM1,200
Active, not recruiting
Phase 2
COVID-19 Prevention of worsening of symptoms in asymptomatic to mild patients by combined use of kakkonto and hochuekkito:Exploratory open-label randomized controlled trialCOVID-19JPRN-jRCTs041200072Ogawa Keiko100
Not yet recruiting
Not Applicable
Cord Blood Therapy to prevent progression of COVID-19 related pneumoniaACTRN12620000478910Monash Health24